Diffuse large B-cell lymphoma with chronic inflammation Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Jan 2025A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Merck Sharp & Dohme LLC — PHASE3

TrialRECRUITING

Jan 2025CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

Washington University School of Medicine — PHASE2

TrialRECRUITING

Sep 2024Pola-ZR2P in Previously Untreated DLBCL

Navy General Hospital, Beijing — PHASE2

TrialRECRUITING

Jul 2024PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Ruijin Hospital

TrialRECRUITING

Mar 2023Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Genmab — PHASE2

TrialACTIVE NOT RECRUITING

Jan 2023Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center — PHASE1, PHASE2

TrialRECRUITING

Jan 2023Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

The First Affiliated Hospital of Soochow University — NA

TrialRECRUITING

Aug 2022Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Seoul National University Hospital — PHASE2

TrialACTIVE NOT RECRUITING

Aug 2022A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Genmab — PHASE2

TrialACTIVE NOT RECRUITING

Jun 2022Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

University of Southampton — PHASE2

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Diffuse large B-cell lymphoma with chronic inflammation.
Check the disease page for updates →

Clinical Trial Landscape

18 active trials

3Phase 3

9Phase 2

2N/A

1Unknown

3PHASE1, PHASE2

18Total recruiting

Search clinical trials for Diffuse large B-cell lymphoma with chronic inflammation →

Recent News & Research

No recent news articles indexed yet for Diffuse large B-cell lymphoma with chronic inflammation.
Search PubMed for Diffuse large B-cell lymphoma with chronic inflammation →

Browse all Diffuse large B-cell lymphoma with chronic inflammation news →

Specialist Network

Top 6 by expertise

Stephen M Ansell, M.D

Dana-Farber - Harvard Cancer Center LAO

📍 ROCHESTER, MN

Score 101 trial5 pubs

Reem Karmali, MD, MD

Northwestern University

📍 CHICAGO, IL

Score 85 trials

Claire Tiger, MD, PhD, M.D

Mayo Clinic

📍 ROCHESTER, MN

Score 81 trial

Stephen M. Ansell, MD, PhD, M.D

Mayo Clinic in Rochester

📍 ROCHESTER, MN

Score 82 trials

Chet Bohac, PharmD, MD, MSc

Executive Medical Director, Clinical Development, Xencor, Inc.

Score 31 trial

Simon Heidegger

Lead Medical Director

Score 02 trials

View all Diffuse large B-cell lymphoma with chronic inflammation specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰